Osimertinib (OSI) vs Standard of Care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

被引：0
|
作者：
Bischoff, H. G. [1 ]
Rueckert, A. [2 ]
Reinmuth, N. [3 ]
Grohe, C. [4 ]
Bohnet, S. [5 ]
zum Bueschenfelde, C. M. [6 ]
机构：
[1] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany
[2] Schwarzwald Baar Klinikum, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
[3] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[4] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany
[5] UKSH Lubeck, Med Klin 3, Lubeck, Germany
[6] St Vincentius Kliniken, Karlsruhe Abt Innere Med 2, Karlsruhe, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
980
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [31] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [32] Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
    Yang, James Chih-Hsin
    Chen, Yuh-Min
    Batra, Ullas
    Do, Kien
    Sitthideatphaiboon, Piyada
    Danchaivijitr, Pongwut
    Lee, Kang-Yun
    Chindaprasirt, Jarin
    Yang, Cheng-Ta
    Chang, Gee-Chen
    Charoentum, Chaiyut
    Ungtrakul, Teerapat
    Moran, Juan Ignacio Hernandez
    Hartmaier, Ryan
    Haskins, Matthew
    Xu, Wanning
    Riess, Jonathan W.
    CANCER RESEARCH, 2024, 84 (07)
  • [33] PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
    Brown, H.
    Vansteenkiste, J.
    Nakagawa, K.
    Cobo Dols, M.
    John, T.
    Barker, C.
    Kohlmann, A.
    Todd, A.
    Saggese, M.
    Chmielecki, J.
    Markovets, A.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S408 - S408
  • [34] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC
    Chen, D.
    Chu, T.
    Chang, Q.
    Zhang, Y.
    Xiong, L.
    Qiao, R.
    Teng, J.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [36] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [37] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR- mutated advanced non-small cell lung cancer (NSCLC)
    Leighl, N.
    Karaseva, N.
    Nakagawa, K.
    Cho, B. -C.
    Gray, J. E.
    Hovey, T.
    Walding, A.
    Ryden, A.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S81 - S82
  • [39] Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
    Zhang, Ping
    Nie, Xin
    Bie, Zhixin
    Li, Lin
    MEDICINE, 2018, 97 (09)
  • [40] ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
    Cho, B. C.
    Piotrowska, Z.
    Le, X.
    Goldberg, S. B.
    Goldman, J.
    De langen, A.
    Okamoto, I.
    Smith, P.
    Mensi, I.
    Maidment, J.
    Hartmaier, R.
    Li, M.
    Doughton, G.
    Patel, G.
    Pease, J.
    Szekeres, P.
    Riess, J.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S598
12345